Navigation Links
Antidepressant Use May Boost Fracture Risk, From Harvard Women's,Health Watch

BOSTON, May 29, 2007 /PRNewswire-USNewswire/ -- Evidence is accumulating that depression is a risk factor for osteoporosis, reports the June 2007 issue of Harvard Women's Health Watch. A recent study found that people ages 50 and over who regularly took antidepressants called selective serotonin reuptake inhibitors (SSRIs) had double the rate of fractures as people not using such medications. Other research points to depression itself as a source of endocrine changes that can damage bone.

Whether the danger comes from depression, the drugs used to treat it, or something else, doctors are paying more attention to this association. During the 1990s, depression began to emerge as a possible cause of bone loss, rather than a result. Scientists studied women who didn't have osteoporosis symptoms or even know they had the condition. They found lower bone mineral density in those who were depressed. Moreover, the link was found in both younger women and women past menopause. Other studies have found a similar relationship, so investigators have been looking at hormones and brain chemicals potentially involved in both depression and bone loss.

Researchers working with an animal model found that depression triggers the release of noradrenaline, which interferes with bone-building cells. Moreover, they found that imipramine-a member of an older class of drugs called tricyclic antidepressants-reversed both depression and depression- induced bone loss.

It may be a long time before the depression-osteoporosis connection is fully clarified. In the meantime, Harvard Women's Health Watch suggests that you continue taking an antidepressant if you already use one; depression is a serious illness that can have profound consequences. You may also want to talk to your doctor about getting a bone density test, and make sure you get adequate calcium.


    Also in this issue:


    -- Update on treating 
IBS

    -- Driving safety and aging

    -- Simpler CPR for cardiac arrest

    -- By the way doctor: Tamoxifen versus aromatase inhibitors for

       breast cancer
 

Harvard Women's Health Watch is available from Harvard Health Publications, the publishing division of Harvard Medical School, for $24 per year. Subscribe at http://www.health.harvard.edu/women or by calling 1-877- 649-9457 (toll free).

Media: Contact Christine Junge at for a complimentary copy of the newsletter, or to receive our press releases directly. Christine_Junge@hms.harvard.edu

CONTACT: Christine Junge of Harvard Health Publications, +1-617-432-4717, Christine_Junge@hms.harvard.edu

Web site: http://www.health.harvard.edu/women//

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Blood Levels of Paliperidone Extended-Release Tablets are Not Increased by Common Antidepressant
2. Six-Week Investigational Study In Adults With Major Depressive Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole Therapy With Antidepressants
3. FDA Proposes New Warnings About Suicidal Thinking, Behavior in Young Adults Who Take Antidepressant Medications
4. CeNeRx BioPharma Announces Positive Phase I Results in First Human Trial of Third Generation RIMA Antidepressant
5. New Cardioprotective Drug Could Provide Boost For Post-Bypass Surgery Heart Health
6. Once-yearly Reclast Significantly Reduced Bone Fractures in Women with Postmenopausal Osteoporosis
7. Bipolar Disorder in Children Difficult to Diagnose, Reports the Harvard Mental Health Letter
8. FDA MedWatch: Avastin (bevacizumab) and Formation of Tracheoesophageal Fistula in a Recent Clinical Study in Patients with Limited-stage Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... 2017 On Wednesday, February 22, 2017, ... out of nine sectors finished the trading sessions in green, ... closing. Major US indices were also mixed at the close ... 5,860.63, slightly down by 0.09%; the Dow Jones Industrial Average ... 500 closed at 2,362.82, down 0.11%. This Thursday morning, Stock-Callers.com ...
(Date:2/23/2017)... 2017 ML Capital Group, Inc. (USOTC: MLCG) ... Highlife Tours , a Colorado -based cannabis ... Puration, Inc. (USOTC: PURA) to enter Colorado,s ... Colorado Highlife Tours acquisition announced today is intended to accelerate MLCG,s ... ...
(Date:2/23/2017)... Wash. and VANCOUVER, British Columbia ... (NASDAQ: OGXI ) today announced its year ... In January 2017, OncoGenex, and Achieve Life ... that they have entered into a definitive merger agreement ... transaction. Upon completion of the proposed merger, Achieve,s stockholders ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... February 23, 2017 , ... Rare Disease Report®, which ... participating in Rare Disease Day events, hosted by the Rare Disease Legislative Advocates ... a website, weekly e-newsletter and quarterly publication, will be conducting interviews with patients ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... content provider for the National Institute for Health and Care Excellence ... organizations in the National Health Service (NHS) to search, order and purchase medical ...
(Date:2/23/2017)... ... 23, 2017 , ... Current Meditation , a new ... throughout the U.S. starting this spring. Current Meditation focuses on “meditation for the ... Current Meditation will be the first meditation concept in the U.S. offering franchising ...
(Date:2/23/2017)... ... February 23, 2017 , ... Top cosmetic and periodontal dentist ... today with a new Indiegogo campaign . Individuals are now able to contribute ... Los Angeles area, either as a participating patient or through an Indiegogo donation. The ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... ... and lobby of a new healthcare contact center in Georgia, PENETRON Specialty Products ... of the nation’s largest healthcare systems recently invested $51 million to purchase and ...
Breaking Medicine News(10 mins):